Started in 2020 by biotech and AI specialists, immunitoAI has built a generative-AI platform designed to create therapeutic antibodies without depending on biological sources like human donors or animal immunisation.  Historically, antibody development is a lengthy, costly process  often taking 4 to 5 years. immunitoAI’s technology aims to compress that timeline to around 11–12 months by using machine-learning models that generate likely high-affinity antibody sequences, which are then validated in the company’s own lab. 

With the freshly raised $6.1 million, led by noted investor Ashish Kacholia and participation from funds such as pi Ventures, Anicut Capital, 3one4 Capital, AC Ventures, and others  immunitoAI plans to expand its research & development capabilities, hire additional biotech and AI talent, and scale up its platform infrastructure. A key focus will be on validating antibody candidates for diseases ranging from auto-immune conditions to cancers and antimicrobial resistance (AMR).

According to the company’s CEO and co-founder, its business model includes three potential paths: (1) licensing developed antibodies (IP) to large pharmaceutical companies, (2) custom-antibody development for clients, and (3) eventually developing proprietary therapeutic antibodies and bringing them to market.  If successful, this could significantly lower costs and accelerate access to novel antibody therapies  especially important for settings with limited resources, such as India and other emerging markets. 

immunitoAI’s approach reflects a growing global shift: using generative AI and computational biology to convert what was once a slow, empirical process into a fast, programmable pipeline. With the new funds, the firm hopes to solidify its position among global next-gen biologics innovators and contribute to more equitable therapeutic access.